Quince Therapeutics (QNCX) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 11, 2026, and will be held virtually, allowing shareholders to participate, submit questions, and vote online.

• Shareholders of record as of April 23, 2026, are eligible to vote on the proposals presented.

• The proxy materials, including the proxy statement and annual report, are available online, and shareholders are encouraged to vote electronically or by mail.

Voting matters and shareholder proposals

• Four main proposals: (1) reverse stock split amendment, (2) ratification of BDO USA, P.C. as auditor, (3) advisory vote on executive compensation, and (4) adjournment/postponement of the meeting if needed.

• The board recommends voting FOR all proposals.

• Shareholders may submit proposals for the 2027 annual meeting by December 31, 2026, for inclusion in proxy materials.

Board of directors and corporate governance

• The board operates under Corporate Governance Guidelines and maintains a classified structure with three-year terms for directors.

• Separate CEO and independent Chairperson roles are maintained to reinforce board independence.

• All non-management directors are independent per Nasdaq and SEC rules; all committees meet independence requirements.

• The board has audit, compensation, and nominating/corporate governance committees, each with written charters.

• Directors are selected based on diverse backgrounds, skills, and experience, with an emphasis on diversity and inclusion.